Assessing patients’ acceptance of their medication to reveal unmet needs: results from a large multi-diseases study using a patient online community

Abstract

BackgroundPatients with chronic conditions are required to take long-term treatments for their disease itself or to prevent any potential health risks. Measuring patient acceptance of their medication should help to better understand and predict patients’ behavior toward treatment. This study aimed to describe the level of patient acceptance toward various long-term treatments in real life using an online patient community.MethodsThis was an observational, cross-sectional study conducted through the French Carenity platform. All Carenity patient members were invited to complete an online questionnaire including the 25-item ACCEptance by the Patients of their Treatment (ACCEPT©) questionnaire. ACCEPT© measures patient acceptance toward their medication and includes one general acceptance dimension (Acceptance/General) and six treatment-attribute specific dimensions (scores 0–100; lowest to highest acceptance): Acceptance/Medication Inconvenience, Acceptance/Long-term Treatment, Acceptance/Regimen Constraints, Acceptance/Side effects, Acceptance/Effectiveness, and Acceptance/Numerous Medications. Patients included in the analysis were treated adults experiencing any chronic diseases and who responded to at least one ACCEPT© item.ResultsAmong the 4193 patients included in the analysis, more than 270 chronic diseases were represented, amidst which 19 included more than 30 patients. Mean ACCEPT© Acceptance/General score for those 19 diseases were 61.2 (SD = 31.9) for type 1 diabetes, 59.8 (SD = 32.3) for asthma, 56.3 (SD = 34.3) for hypertension, 52.0 (SD = 32.2) for chronic obstructive pulmonary disease, 51.7 (SD = 27.0) for epilepsy, 50.1 (SD = 33.1) for bipolar disorder, 49.9 (SD = 33.1) for type 2 diabetes, 48.6 (SD = 31.6) for multiple sclerosis, 46.1 (SD = 34.5) for Crohn’s disease/ulcerative colitis, 44.3 (SD = 31.5) for depression, 42.8 (SD = 31.5) for lupus, 42.3 (SD = 33.0) for arthrosis, 41.8 (SD = 32.6) for Parkinson’s disease, 40.5 (SD = 32.2) for rheumatoid arthritis, 38.6 (SD = 31.7) for breast cancer, 36.4 (SD = 36.4) for myocardial infarction, 35.8 (SD = 32.0) for ankylosing spondylitis, 34.1 (SD = 32.3) for psoriasis, and 33.7 (SD = 31.7) for fibromyalgia.ConclusionsThis first of its kind study enabled ACCEPT© data to be collected in real life for a variety of chronic diseases. These data may help in evaluating and interpreting levels of acceptance in future studies and provide valuable insights about patient priorities and current unmet needs.

Perspective of an International Online Patient and Caregiver Community on the Burden of Spasticity and Impact of Botulinum Neurotoxin Therapy: Survey Study

“…The survey was conducted in France, Germany, Italy, Spain, the United Kingdom, and the United States between November 10, 2017, and February 28, 2018, using an established online approach [ 30 - 32 ]. Patients or caregivers of patients with spasticity who were members of the Carenity platform were invited by email to complete a questionnaire, presented in the local language, translated by a specialized agency and reviewed by local Carenity community managers.…”

Core Values that Influence the Patient—Healthcare Professional Power Dynamic: Steering Interaction towards Partnership

“…Patients need to be open about personal priorities and goals that would hinder adherence to treatment. As they may not be immediately aware of these [ 56 ], they would need time to understand the complexities of treatment and make adjustments before they can evaluate the benefits and risks [ 36 , 57 ] and even articulate them [ 58 ]. Essential to patient participation is their ability to accurately and concisely communicate accrued knowledge [ 16 , 22 ].…”

“…Essential to patient participation is their ability to accurately and concisely communicate accrued knowledge [ 16 , 22 ]. HCPs on the other hand should favour holistic models over the mechanist approach in their interactions with patients, so as to enable some reconciliation between the core values and principles that drive each side’s actions [ 7 ] and highlight what constitutes “acceptable risk” for both parties [ 57 ]. In addition, this would facilitate continued open discussion and adjustments to the therapeutic plan, allowing for collaborative goal setting and providing shared goals to work towards [ 19 ].…”

Síndrome da Fibromialgia e Transtorno Depressivo: uma análise de estudos transversais e longitudinais

“…(maior aceitação em relação a SFM) (LAMBERT et al, 2018). A limitação deste estudo foi não analisar os pacientes com SFM de maneira simultânea ao TD, não sendo possível inferir a adesão ao tratamento nesse grupo comum.…”